Why the Lifehealthcare Group Ltd share price could be a bargain

Lifehealthcare Group Ltd (ASX:LHC) shares could be a bargain.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a shocking set of interim results were released two weeks ago, Lifehealthcare shares fell off a cliff, losing 45% of their value in the past month to a low of $1.28.

Shares subsequently recovered by soaring 15% on Friday to $1.52 as some investors took advantage of the low prices to top up their holding – but is the company really good value, or could things deteriorate further?

(For full disclosure, I had a buy order in at $1.28 – which I've now cancelled – but missed out on shares by a whisker)

The 'Buy' case

  • Defensive healthcare demand is a 'macro' tailwind for the company, supported by a robust health insurance system
  • Room to grow through acquisition in a fragmented market
  • Each acquisition expands the company's footprint and allows cross-selling as well as expansion into adjacent segments

The 'Sell' case

  • Funding situation is unattractive with poor cash flow and rising debt, as well as potentially paying a (reduced) dividend through debt
  • Potential for government review into healthcare to impact prosthetic pricing, which would hurt a major source of high-margin sales
  • Blowout in operating costs including working capital suggests business is not particularly scalable

If we double Lifehealthcare's recent Net Profit After Tax to approximate full-year earnings, this suggests shares are decent value at today's levels, trading on a Price to Earnings (P/E) ratio of around 10, substantially below the market average.

At least, it looks as though the potential for a hit to profitability from changes to the healthcare system is already priced into the company. Management has implied they do not believe Lifehealthcare's prosthetics business is at risk from this review, as a result of media reports that have 'misrepresented implant price inflation and overestimated public / private price variation'.

Lifehealthcare is small, and even at share prices of $3 apiece the company has a market cap of only ~$130 million. This means that additional expenses like the recent $1.1m in acquisition costs can have a big impact on profitability. Looking through the results to future periods, shareholders might expect Lifehealthcare profits to experience a rebound as these one-off expenses work their way through the business.

Shareholders might also take some heart from management's statement that $3.8m of the $8.7m increase in working capital costs was to 'support stronger second half pipeline'. A further $1.1m came from higher receivables from the recent MVA acquisition.

Interestingly, similar business Paragon Care Ltd. (ASX: PGC) also reported poorer cash flow during the half, which it attributed to timing differences and an increase in inventory expenses, just like Lifehealthcare. This could indicate a wider industry trend rather than poor performance at Lifehealthcare.

Nearly all businesses promise improvement after a disappointing set of results, but it currently appears that much of the downside is already priced into Lifehealthcare shares. Based on the known facts and management statements, Lifehealthcare could be set to see improving business performance over the next 12 months or so, and I am looking to top up my holding, when Foolish trading rules permit.

Motley Fool contributor Sean O'Neill owns shares of LifeHealthcare Group Limited. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »